Atlas Trials

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Clinical trial NCT03316131 · COMPLETED

Trial details

NCT number
NCT03316131
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Asymptomatic Hyperuricemia
Start date
2017-10-25
Primary completion
2018-07-19
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.